News

Barriers to Epilepsy Care Continue to Frustrate

BALTIMORE – People with epilepsy – and their physicians – report that they continue to encounter barriers to optimal care, according to Dr. Sandra Helmers. Read more…

Also posted in Home-News, Press Room | Comments closed

Heroes Night Gala Photos are Available for Viewing

Interested in viewing photos from the 2011 Heroes Night Gala? Visit nagleweb.com  and browse galleries devoted to the awards ceremony, candids or sponsorship wall portraits. The photos, taken by the wonderful photographers from Nagle Photography, capture the joyful evening of awards, awareness and activism. For more information on Nagle Photography and their spectacular work, click this [...]

Also posted in Home-News, Press Room | Comments closed

Study finds superior drug combo for difficult-to-control epilepsy

A combination of two common drugs, lamotrigine and valproate, is more effective in treating difficult-to control epilepsy than other anti-epileptic regimens, according to a University of Washington report to be published online this week inNeurology, the journal of the American Academy of Neurology. Read more…

Also posted in Home-News, Press Room | Comments closed

Research Documents Seizure Trends in Women with Catamenial Epilepsy

Newswise — Baltimore, December 3 – In women of childbearing age with epilepsy, seizure exacerbation may occur either at the time of menstruation or ovulation. Investigators in a specialized epilepsy center have analyzed the data on a group of patients with seizures associated with their menstrual cycles (catamenial seizures) for type of epilepsy, seizure frequency, [...]

Also posted in Home-News, Press Room | Comments closed

Novel Approach Reveals Potential Mechanism Underlying Dravet Syndrome

Newswise — Baltimore, December 3 – Scientists investigating the fundamental cause of Dravet syndrome, a severe childhood epilepsy, have reprogrammed fibroblasts, a type of skin cell, from Dravet patients and generated patient-specific neurons. Further study revealed that these patient-derived neurons showed increased excitability, abnormal neuronal behavior that can produce seizures. Read more…

Also posted in Home-News, Press Room | Comments closed

EFGC’s Studio E artwork on display at American Epilepsy Society Annual Meeting

BALTIMORE–(BUSINESS WIRE)–Today, Lundbeck announced its Studio E: The Epilepsy Art Therapy Program will be made available in 21 cities next year through partnerships with local Epilepsy Foundation affiliates across the country. Earlier this year, Studio E was launched to offer group art therapy sessions as an outlet of expression for people with epilepsy. In celebration of artwork created during [...]

Also posted in Home-News, Press Room | Comments closed

Vascular risk linked to long-term antiepileptic drug therapy

New research reveals that patients with epilepsy who were treated for extended periods with older generation antiepileptic drugs (AEDs) may be at increased risk for developing atherosclerosis, a common disorder known as hardening of the arteries. According to the findings now available in Epilepsia, the journal of the International League Against Epilepsy (ILAE), the vascular risk [...]

Also posted in Home-News, Press Room | Comments closed

Brain Stimulator Shown to Reduce ‘Untreatable’ Epileptic Seizures

Brain stimulation, already approved by the U.S. Food and Drug Administration for the treatment of Parkinson’s disease and essential tremor, has now been shown to offer significant relief to patients with intractable seizures for whom drugs and other treatments have not worked. Read more…

Also posted in Home-News, Press Room | Comments closed

Abbott Said to Agree to Pay $1.3 Billion for Depakote Suits

Abbott Laboratories agreed to pay at least $1.3 billion to settle claims by the U.S. government and 24 states alleging the company illegally marketed its Depakote epilepsy drug, people familiar with the accords said. Read more…

Also posted in Home-News, Press Room | Comments closed

FDA approves Onfi to treat severe type of seizures

On Oct. 21, the U.S. Food and Drug Administration approved Onfi tablets (clobazam) for use as an adjunctive (add-on) treatment for seizures associated with Lennox-Gastaut syndrome in adults and children 2 years of age and older. As Onfi is intended to treat a disease or condition that affects fewer than 200,000 people in the United [...]

Also posted in Home-News, Press Room | Comments closed